3 results
Approved WMOPending
To evaluate the long-term safety and tolerability of ralinepag (ADP811) in subjects who participated in a preceding Phase 2 or Phase 3 study of ralinepag.
Approved WMORecruiting
To demonstrate the effect of ralinepag on the time to first adjudicated protocol-defined clinical worsening event in subjects with PAH.
Approved WMORecruiting
Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity• Characterize the pharmacokinetics (PK) of bemarituzumab Part 2 (phase 2)Primary:• To evaluate preliminary…